According to the network of Anhui Medical Insurance Bureau, adalimumab belongs to Class B medical insurance, and the reimbursement rate is about 40% to 60%. Due to different regions and different reimbursement rates, patients need to consult the local medical insurance bureau themselves.
Adalimumab is a drug negotiated during the national agreement period, which has been included in the national medical insurance drug list and belongs to the category B reimbursement scope. Individuals pay 30% in advance, and the rest are implemented according to the policy of the insured place.